Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder
Russell
R
Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911-2412, USA. RJ_Schilder@fccc.edu
Molina
Arturo
A
Bartlett
Nancy
N
Witzig
Thomas
T
Gordon
Leo
L
Murray
James
J
Spies
Stewart
S
Wang
Hua
H
Wiseman
Gregory
G
White
Christine
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000401:mortality / Q000532:radiotherapy*; D008224:Lymphoma, Follicular / Q000401:mortality / Q000532:radiotherapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy; D013921:Thrombocytopenia / Q000401:mortality / Q000532:radiotherapy*; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan